DRAK2 peptide
GTX28454
Overview
- SupplierGeneTex
- Product NameDRAK2 peptide
- Delivery Days Customer9
- Application Supplier NoteThe peptide is used for blocking the activity of DRAK2 (GTX28419). Incubatingthe peptide with equal volume of antibody for 30 min at 37C usually completely blocks theantibody activity in Western blotting.
- ApplicationsNeutralisation/Blocking
- CertificationResearch Use Only
- Concentration0.20 mg/ml
- ConjugateUnconjugated
- FormulationLiquid
- Scientific DescriptionApoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase related apoptosis inducing protein kinases). DRAKs contain an N terminal kinase domain and a C terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues.
- Storage Instruction-20°C
- UNSPSC12352202